BACKGROUND Paroxysmal nocturnal hemoglobinuria (PNH) is an acquired clonal disorder characterized by chronic complement-mediated hemolysis. Eculizumab, a humanized monoclonal antibody against the terminal complement protein C5, potently reduces chronic intravascular hemolysis. We tested the clinical efficacy and safety of a 24-week treatment with eculizumab in 6 Korean patients with PNH. METH...

BACKGROUND Intravascular hemolysis in sickle cell anemia could contribute to complications associated with nitric oxide deficiency, advancing age, and increased mortality. We have previously reported that intense hemolysis is associated with increased risk of vascular complications in a small cohort of adults with sickle cell disease. These observations have not been validated in other populati...

A patient with chronic moderate neutropenia, acute hemolysis, and pyrexia was found to be infected with a novel hemoplasma species. A clinical response to doxycyline was noted, and moxifloxacin was added subsequently to aid infection clearance. This represents the first report of hemolysis in association with confirmed hemoplasma infection in a human.

vision of the possible mechanism(s) involved in the hemolytic crisis brought on by other comorbid conditions, such as sepsis. Along the same lines, there is evidence that the HbF levels, an important regulatory mechanism of SCA severity and hemolysis, govern MP concentration by acting on specific MP subtypes. We can imagine that, in SCA children, a storm of various (mainly platelet-derived) pro...

Background Chronic liver diseases can be associated with autoimmune diseases. their association hemolytic anemia (AIHA) is poorly studied. Objectives Our objective was to study the prevalence and characteristics of AIHA in chronic Methods We performed a retrospective analysis data from consecutive patients followed our department for recruited January 2010 December 2019. The diagnosis AHAI reta...

Paroxysmal nocturnal hemoglobinuria (PNH) is a rare chronic hemolytic anemia characterized by an acquired defect of the erythrocyte which renders it susceptible to hemolysis by normal human serum. Previous reports have indicated that magnesium and factors resembling the components of complement are required for the hemolysis in vitro of PNH erythrocytes by normal serum (1, 2). Recently a natura...

The clinical hallmark of paroxysmal nocturnal hemoglobinuria (PNH) is chronic intravascular hemolysis that is a consequence of unregulated activation of the alternative pathway of complement (APC). Intravascular hemolysis can be inhibited in patients by treatment with eculizumab, a monoclonal antibody that binds complement C5 thereby preventing formation of the cytolytic membrane attack complex...

Paroxysmal nocturnal hemoglobinuria (PNH) is a rare chronic hemolytic anemia characterized by an acquired defect of the erythrocyte which renders it susceptible to hemolysis by normal human serum. Previous reports have indicated that magnesium and factors resembling the components of complement are required for the hemolysis in vitro of PNH erythrocytes by normal serum (1, 2). Recently a natura...